1-(3-((6,7-Bis(2-methoxyethoxy)quinazolin-4-yl)amino)phenyl)ethan-1-one

Catalog No. :
ACAFME852
CAS No. :
1354727-63-1
Molecular Formula :
C22H25N3O5
Molecular Weight :
411.46

IUPAC Name:1-(3-((6,7-bis(2-methoxyethoxy)quinazolin-4-yl)amino)phenyl)ethan-1-one

1-(3-((6,7-Bis(2-methoxyethoxy)quinazolin-4-yl)amino)phenyl)ethan-1-one structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
No pack options available.

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name1-(3-((6,7-Bis(2-methoxyethoxy)quinazolin-4-yl)amino)phenyl)ethan-1-one
IUPAC Name1-(3-((6,7-bis(2-methoxyethoxy)quinazolin-4-yl)amino)phenyl)ethan-1-one
Molecular FormulaC22H25N3O5
Molecular Weight411.46
SMILESCC(C1=CC=CC(NC2=C3C=C(OCCOC)C(OCCOC)=CC3=NC=N2)=C1)=O
InChI KeyFMRDQKHUXMVMTP-UHFFFAOYSA-N
SynonymErlotinib Impurity 107;1-(3-(6,7-bis(2-methoxyethoxy)quinazolin-4-ylamino)phenyl)ethanone;Erlotinib Impurity 24 HCl;Ethanone, 1-[3-[[6,7-bis(2-methoxyethoxy)-4-quinazolinyl]amino]phenyl]-
CAS No.1354727-63-1

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P312-P330-P362-P403+P233-P501

Synthetic Route by SureRoute

1. ACAFME852 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACLRNS458 route compound structure diagram
    ACLRNS45899-03-6 In Stock
  2. Plus
  3. ACABYW182 route compound structure diagram
    ACABYW182183322-18-1 In Stock
  4. Then
  5. ACAFME852 route product structure diagram
    ACAFME8521354727-63-1
Inquiry

2. ACAFME852 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACAFME852 route product structure diagram
    ACAFME8521354727-63-1
Inquiry

Comments (0)